Olanzapine (Zyprexa Relprevv) vs Risperidone (Risperdal Consta)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Olanzapine (Zyprexa Relprevv)

Marketed by Cheplapharm Arzneimittel GmbH and partners

Approved in Schizophreniasmall molecule
Reliable signal

NCT00088478 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial of 402 patients. All three tested doses of the long-acting olanzapine injection produced a significantly greater reduction in psychiatric symptom severity (PANSS) than placebo.

Reported efficacy

Demonstrate superiority of IM olanzapine depot 300 mg/2 weeks, 405 mg/4 weeks, and 210 mg/2 weeks dosages compared with placebo in the treatment of patients with schizophrenia: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each). (met)

Result source: NCT00088478

Risperidone (Risperdal Consta)

Marketed by Johnson & Johnson

Approved in Schizophreniasmall molecule
Reliable signal

NCT00253136 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial with 458 participants, using change in a standard psychiatric symptom scale as the primary measure. The FDA product label for this pivotal trial reports that 47% of patients on the 25 mg dose showed a clinically meaningful improvement, compared with 17% on placebo.

Reported efficacy

Change from baseline to the end of double-blind treatment in the PANSS (Positive and Negative Syndrome Scale for Schizophrenia) total score: Clinical improvement (>=20% PANSS total score reduction): 47% (Risperdal Consta 25mg) vs 17% (placebo); design (randomized, double-blind, placebo-controlled, 25/50/75mg arms, 12 weeks, Nov 1999-Dec 2000) and this was the pivotal FDA-registration trial for Risperdal Consta, matching NCT00253136's CT.gov record exactly. (met)

Result source: NCT00253136

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointOlanzapine (Zyprexa Relprevv)Risperidone (Risperdal Consta)
PANSS total, change—Not posted · NCT00088491-9.3 vs -1.1vs Quetiapinewk 104 · n 326NCT00216476
1 other result
  • -11.7 vs -13 wk 52 · n 17 · Phase 4 · secondary NCT00992407
CGI-S, change-0.4 vs -0.3vs Oral Olanzapinewk 104 · n 121NCT00320489-0.3 vs 0.1vs Quetiapinewk 104 · n 326NCT00216476
1 other result
  • -0.6 vs -0.7 wk 52 · n 17 · Phase 4 · secondary NCT00992407
PANSS response—Not posted · NCT00088491—Not posted · NCT00216580
PSP, change—Not posted · NCT000884915.3 vs 6.0vs Risperidone Tabletswk 52 · n 17NCT00992407
Relapse (% of patients)20.1% vs 18.5%vs Oral Olanzapinen 264NCT003204895% vs 32.6%vs Risperidonewk 52 · n 40NCT00330551
1 other result
  • 34.4% vs 16.1% wk 104 · n 32 · Phase 4 · secondary NCT00246259

PANSS total, change

Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491
Risperidone (Risperdal Consta)
-9.3 vs -1.1vs Quetiapinewk 104 · n 326NCT00216476
1 other result
  • -11.7 vs -13 wk 52 · n 17 · Phase 4 · secondary NCT00992407

CGI-S, change

Olanzapine (Zyprexa Relprevv)
-0.4 vs -0.3vs Oral Olanzapinewk 104 · n 121NCT00320489
Risperidone (Risperdal Consta)
-0.3 vs 0.1vs Quetiapinewk 104 · n 326NCT00216476
1 other result
  • -0.6 vs -0.7 wk 52 · n 17 · Phase 4 · secondary NCT00992407

PANSS response

Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491
Risperidone (Risperdal Consta)
—Not posted · NCT00216580

PSP, change

Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491
Risperidone (Risperdal Consta)
5.3 vs 6.0vs Risperidone Tabletswk 52 · n 17NCT00992407

Relapse (% of patients)

Olanzapine (Zyprexa Relprevv)
20.1% vs 18.5%vs Oral Olanzapinen 264NCT00320489
Risperidone (Risperdal Consta)
5% vs 32.6%vs Risperidonewk 52 · n 40NCT00330551
1 other result
  • 34.4% vs 16.1% wk 104 · n 32 · Phase 4 · secondary NCT00246259
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Olanzapine (Zyprexa Relprevv): 6 of 6 rows · Risperidone (Risperdal Consta): 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOlanzapine (Zyprexa Relprevv)
Rows use multiple source trials
Risperidone (Risperdal Consta)
Rows use multiple source trials
CGI-S
absolute change · score
No placebo or comparator arm
-0.17 score @ 313wka,b,c,d
NCT00088465 · Phase 3 · registry result, not featured evidence
-0.89 score @ 96wka,b,c,d
NCT00269919 · Phase 4 · registry result, not featured evidence
PANSS Total
absolute change · score
No placebo or comparator arm
0.3 score @ 330wka,b,c,e
NCT00088465 · Phase 3 · registry result, not featured evidence
18.24 score @ 96wka,b,c,e
NCT00269919 · Phase 4 · registry result, not featured evidence
Dropout rate
54.9%f
NCT00320489 · Phase 3 · monotherapy
show 1 more result
60.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
38.4%f
NCT00132314 · Phase 3
show 14 more results
5.9%CT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
0%CT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
14.3%HBT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
5.9%HBT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
25%Long-acting Injectable Risperidone
NCT00330551 · Phase 4 · registry result, not featured evidence
—Long-acting Injectible Risperidone
NCT00330551 · Phase 4 · registry result, not featured evidence
29.5%
NCT00539071 · Phase 4 · registry result, not featured evidence
83.8%
NCT00992407 · Phase 4 · registry result, not featured evidence
26.5%
NCT00130923 · Phase 4 · registry result, not featured evidence
31.8%
NCT00216671 · Phase 4 · registry result, not featured evidence
63.6%
NCT00246259 · Phase 4 · registry result, not featured evidence
67.5%
NCT00269919 · Phase 4 · registry result, not featured evidence
45.3%
NCT01726335 · Phase 4 · registry result, not featured evidence
31.9%
NCT00216476 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
9.8%f
NCT00320489 · Phase 3 · monotherapy
show 1 more result
8.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
—f
NCT00132314 · Phase 3
show 14 more results
—CT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
—CT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
—HBT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
—HBT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
—Long-acting Injectable Risperidone
NCT00330551 · Phase 4 · registry result, not featured evidence
—Long-acting Injectible Risperidone
NCT00330551 · Phase 4 · registry result, not featured evidence
—
NCT00539071 · Phase 4 · registry result, not featured evidence
18.9%
NCT00992407 · Phase 4 · registry result, not featured evidence
—
NCT00130923 · Phase 4 · registry result, not featured evidence
5.5%
NCT00216671 · Phase 4 · registry result, not featured evidence
11.4%
NCT00246259 · Phase 4 · registry result, not featured evidence
—
NCT00269919 · Phase 4 · registry result, not featured evidence
7.5%
NCT01726335 · Phase 4 · registry result, not featured evidence
1.8%
NCT00216476 · Phase 3 · registry result, not featured evidence
Serious AEs
9.5%f
NCT00320489 · Phase 3 · monotherapy
show 1 more result
18.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
51.3%f
NCT00132314 · Phase 3
show 14 more results
18.8%CT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
8.3%CT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
8.3%HBT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
0%HBT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
—Long-acting Injectable Risperidone
NCT00330551 · Phase 4 · registry result, not featured evidence
5%Long-acting Injectible Risperidone
NCT00330551 · Phase 4 · registry result, not featured evidence
6.4%
NCT00539071 · Phase 4 · registry result, not featured evidence
0%
NCT00992407 · Phase 4 · registry result, not featured evidence
32.7%
NCT00130923 · Phase 4 · registry result, not featured evidence
16.4%
NCT00216671 · Phase 4 · registry result, not featured evidence
4.5%
NCT00246259 · Phase 4 · registry result, not featured evidence
15.4%
NCT00269919 · Phase 4 · registry result, not featured evidence
5.7%
NCT01726335 · Phase 4 · registry result, not featured evidence
19.1%
NCT00216476 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
f
weight increased 16.7%
insomnia 11%
anxiety 9.8%
NCT00320489 · Phase 3 · monotherapy
show 1 more result
weight increased 14.4%
anxiety 9.7%
insomnia 9.7%
NCT00088465 · Phase 3 · registry result, not featured evidence
f
insomnia 18.7%
headache 17.1%
vomiting 13.9%
NCT00132314 · Phase 3
show 13 more results
bmi increase normal/overweight to obese 31.3%
ldl or triglyceride increase 25%
prolactin related symptom 12.5%
NCT00333177 · Phase 4 · registry result, not featured evidence
bmi increase normal/overweight to obese 25%
prolactin related symptom 16.7%
ldl or triglyceride increase 8.3%
NCT00333177 · Phase 4 · registry result, not featured evidence
ldl or triglyceride increase 41.7%
prolactin related symptom 16.7%
bmi increase normal/overweight to obese 0%
NCT00333177 · Phase 4 · registry result, not featured evidence
bmi increase normal/overweight to obese 12.5%
ldl or triglyceride increase 6.3%
prolactin related symptom 6.3%
NCT00333177 · Phase 4 · registry result, not featured evidence
bmi increase from normal or overweight to obese 17.5%
prolactin related 7.5%
lipid increase 5%
NCT00330551 · Phase 4 · registry result, not featured evidence
non-serious adverse events 16.7%
NCT00539071 · Phase 4 · registry result, not featured evidence
akathisisa 10%
anxiety 10%
muscle rigidity 10%
NCT00992407 · Phase 4 · registry result, not featured evidence
insomnia 10.2%
pain 10.2%
vomiting 10.2%
NCT00130923 · Phase 4 · registry result, not featured evidence
insomnia 8.2%
akathisia 7.3%
weight increased 7.3%
NCT00216671 · Phase 4 · registry result, not featured evidence
headache 34.1%
insomnia 29.5%
fatigue 25%
NCT00246259 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 20.5%
akathisia 12.8%
vision blurred 10.3%
NCT00269919 · Phase 4 · registry result, not featured evidence
libido decreased 22.6%
weight increased 13.2%
blood prolactin increased 11.3%
NCT01726335 · Phase 4 · registry result, not featured evidence
hyperprolactinaemia 13.1%
anxiety 11.9%
insomnia 10.9%
NCT00216476 · Phase 3 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 4 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 96 weeks versus 313 weeks.
  5. eAssessment timepoints differ: 96 weeks versus 330 weeks.
  6. fPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Olanzapine (Zyprexa Relprevv)

Time to Discontinuation Any Reason Median 21.17 vs 22.26 Oral Olanzapine months
time to event · months
NCT00320489 · Phase 3 · monotherapy · converted to months from 644.5 days as posted
QLS Total 8.15 vs 7.24 Oral Olanzapine score @ 104wk
absolute change · score
NCT00320489 · Phase 3 · monotherapy
SF-36 Physical Component Summary 0.43 vs 0.84 Oral Olanzapine score @ 104wk
absolute change · score
Physical Score Detail Change Week 104 (n=124,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Physical Functioning 1.35 vs 2.44 Oral Olanzapine score @ 104wk
absolute change · score
Physical Functioning Change Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 - Role Physical 10.7 vs 13.76 Oral Olanzapine score @ 104wk
absolute change · score
Role-Physical Change at Week 104 (n=130,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Bodily Pain 3.23 vs -0.6 Oral Olanzapine score @ 104wk
absolute change · score
Bodily Pain Change at Week 104 (n=131,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 General Health 2.69 vs 5.32 Oral Olanzapine score @ 104wk
absolute change · score
General Health Change at Week 104 (n=128,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Social Functioning 8.13 vs 5.1 Oral Olanzapine score @ 104wk
absolute change · score
Social Functioning Change at Week 104 (n=131,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Vitality 7.95 vs 9.01 Oral Olanzapine score @ 104wk
absolute change · score
Vitality Change at Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 - Role Emotional 16.38 vs 17.59 Oral Olanzapine score @ 104wk
absolute change · score
Role-Emotional Change at Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
EQ-5D 0.07 vs 0.09 Oral Olanzapine score @ 104wk
absolute change · score
NCT00320489 · Phase 3 · monotherapy
SUMD Total -0.72 vs -0.5 Oral Olanzapine score @ 104wk
absolute change · score
Total Score (Items 1-5) Change to Week 104
NCT00320489 · Phase 3 · monotherapy

+ 11 further endpoints in the CSV export.

Risperidone (Risperdal Consta)

Hospitalization-free Survival NA vs 23.64 Oral Antipsychotic months
time to event · months
NCT00132314 · Phase 3
MCCB Composite 6.7 score @ 52wk
absolute change · score
No placebo or comparator arm
NCT00333177 · Phase 4 · registry result, not featured evidence
show 3 more results
0.9 score @ 52wk
NCT00333177 · Phase 4 · registry result, not featured evidence
3.9 score @ 52wk
NCT00333177 · Phase 4 · registry result, not featured evidence
5.9 score @ 52wk
NCT00333177 · Phase 4 · registry result, not featured evidence
Gfs Role 2.9 score @ 26wk
absolute change · score
No placebo or comparator arm
NCT00333177 · Phase 4 · registry result, not featured evidence
show 7 more results
0.92 score @ 26wk
NCT00333177 · Phase 4 · registry result, not featured evidence
1.27 score @ 26wk
NCT00333177 · Phase 4 · registry result, not featured evidence
-0.82 score @ 26wk
NCT00333177 · Phase 4 · registry result, not featured evidence
2.7 score @ 52wk
NCT00333177 · Phase 4 · registry result, not featured evidence
1.69 score @ 52wk
NCT00333177 · Phase 4 · registry result, not featured evidence
2.43 score @ 52wk
NCT00333177 · Phase 4 · registry result, not featured evidence
0.18 score @ 52wk
NCT00333177 · Phase 4 · registry result, not featured evidence
WBI Quality Work/School Performance -6.5 score @ 52wk
absolute change · score
No placebo or comparator arm
NCT00333177 · Phase 4 · registry result, not featured evidence
show 3 more results
8.8 score @ 52wk
NCT00333177 · Phase 4 · registry result, not featured evidence
-3.4 score @ 52wk
NCT00333177 · Phase 4 · registry result, not featured evidence
0 score @ 52wk
NCT00333177 · Phase 4 · registry result, not featured evidence
Relapse 7.1% (n=28)
event count · % of participants
No placebo or comparator arm
NCT00333177 · Phase 4 · registry result, not featured evidence · converted to % from 2 participants as posted
show 1 more result
35.7% (n=28)*
NCT00333177 · Phase 4 · registry result, not featured evidence · converted to % from 10 participants as posted
MCCB Composite 3.5 vs 4.4 Risperidone score @ 52wk
absolute change · score
NCT00330551 · Phase 4 · registry result, not featured evidence
SUMD Total 0.07 vs -0.24 Risperidone score @ 52wk
absolute change · score
NCT00330551 · Phase 4 · registry result, not featured evidence
show 1 more result
-4.8 vs -3.5 Risperidone Tablets score @ 52wk
NCT00992407 · Phase 4 · registry result, not featured evidence
PANSS Positive 21.4 score @ 6wk
absolute change · score
No placebo or comparator arm
PANSS Positive 6 Weeks
NCT00539071 · Phase 4 · registry result, not featured evidence
PANSS Positive 20 score @ 12wk
absolute change · score
No placebo or comparator arm
PANSS Positive 12 Weeks
NCT00539071 · Phase 4 · registry result, not featured evidence
PANSS Positive 19.1 score @ 18wk
absolute change · score
No placebo or comparator arm
PANSS Positive 18 Weeks
NCT00539071 · Phase 4 · registry result, not featured evidence
PANSS Positive 18.1 score @ 24wk
absolute change · score
No placebo or comparator arm
PANSS Positive 24 Weeks
NCT00539071 · Phase 4 · registry result, not featured evidence
PANSS Negative 19.5 score @ 6wk
absolute change · score
No placebo or comparator arm
PANSS Negative 6 Weeks
NCT00539071 · Phase 4 · registry result, not featured evidence

+ 29 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olanzapine (Zyprexa Relprevv)'s landscape · Risperidone (Risperdal Consta)'s landscape